Physician profile
Nicolas E Makhoul
NPI 1639109515
$3,090.83
in general payments reported to CMS, 2019-2025
25 companies · $749 in 2025
The $749 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $242 · 2021: $225 · 2022: $400 · 2023: $326 · 2024: $1,149 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $496.62 | 2020-2024 | Shingrix |
| Roche Molecular Systems, INC. | $400.00 | 2022 | |
| Lilly USA, LLC | $374.14 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.66 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $215.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $172.37 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $166.75 | 2024-2025 | Keytruda, Welireg |
| Pfizer INC. | $142.32 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $95.37 | 2023-2025 | Orgovyx |
| Astrazeneca Pharmaceuticals LP | $94.80 | 2024-2025 | Airsupra, Breztri |
| Janssen Biotech, INC. | $89.63 | 2025 | Erleada |
| Telix Pharmaceuticals | $82.35 | 2023-2024 | Illuccix |
| Novo Nordisk INC | $69.45 | 2023-2025 | Wegovy, Rybelsus |
| Teleflex LLC | $60.45 | 2025 | Barrigel, Urolift |
| Novartis Pharmaceuticals Corporation | $55.52 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $50.90 | 2024-2025 | Ams 700, Bulkamid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.95 | 2024 | Xifaxan |
| Astellas Pharma US INC | $39.75 | 2023-2024 | Veozah |
| Amgen INC. | $35.85 | 2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $29.98 | 2024 | |
| Bluewind Medical | $29.06 | 2024 | Revi |
| Olympus America INC. | $27.69 | 2024 | Itind System |
| Abc Home Medical Supply, INC. | $24.71 | 2025 | |
| Dynavax Technologies Corporation | $19.04 | 2023 | Heplisav-B |
| Therapeuticsmd, INC. | $16.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Makhoul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.